Parnax Lab (PARNAXLAB) | Stock Overview & Key Data
Parnax Lab Performance Comparison
Stock Range
Today's Range
Low: ₹122.50
High: ₹137.25
on August 26, 2025
52 Week Range
Low: ₹81.00
High: ₹193.50
on March 4, 2025
on November 7, 2024
All-Time High: ₹193.50 on November 4, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR1.4B
EPS
9.43
P/E Ratio (TTM)
12.99
Forward P/E
N/A
P/B Ratio
1.69
PEG Ratio
-0.73
Div. Yield
N/A
ROE
13.84%
Beta
0.461
Debt to Equity
83.52
Financial Highlights
Profitability
Gross Margin
43.83%
Operating Margin
10.29%
Profit Margin
5.67%
Returns and Earnings
Return on Assets (TTM)
6.07%
Return on Equity (TTM)
13.84%
EBITDA
INR273.4M
Net Income (TTM)
INR108.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR166.29
Quarterly Revenue Growth (YoY)
6.50%
Quarterly Earnings Growth (YoY)
-17.90%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Parnax Lab PARNAXLAB | 1.41B Small-cap | 6.15% | 9.38% | 43.81% | 42.55% | -21.14% | 10.65% | 44.25% | 647.19% |
| Sun Pharmaceutical SUNPHARMA | 3.97T Large-cap | -1.56% | -5.93% | -4.47% | -2.81% | -15.28% | -12.15% | 84.04% | 212.28% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | 1.83% | -5.98% | -8.11% | 10.23% | 1.93% | 21.53% | 72.05% | 92.06% |
| Sun Pharma Advanced SPARC | 47.41B Small-cap | -3.03% | -4.92% | -13.36% | 17.11% | -28.95% | -35.58% | -37.00% | -18.78% |
| Aarti Drugs AARTIDRUGS | 44.09B Small-cap | -4.22% | -10.91% | 0.60% | 27.06% | 3.19% | -19.35% | 7.87% | -34.19% |
| Sequent Scientific SEQUENT | 43.69B Small-cap | -1.29% | -0.86% | -5.35% | 15.09% | -5.81% | 6.29% | 51.90% | 29.84% |
Ownership & Short Interest
Insider Ownership
73.92%
Institutional Ownership
0.00%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
5K
Average 90-Day Volume
7K
Parnax Lab Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Parnax Lab would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PARNAXLAB's 52-week high and low?
- In the last 52 weeks, Parnax Lab reached a high of ₹193.50 (on November 7, 2024) and a low of ₹81.00 (on March 4, 2025).
- What is the market cap and P/E ratio for PARNAXLAB?
- Curious about Parnax Lab's size and valuation? Its market capitalization stands at 1.41B. When it comes to valuation, the P/E ratio (trailing twelve months) is 12.99, and the forward P/E (looking ahead) is N/A.
- Does PARNAXLAB pay dividends? If so, what's the yield?
- As for dividends, Parnax Lab isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Parnax Lab's main competitors or similar companies to consider before investing?
When looking at Parnax Lab, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.97T Healthcare Drug Manufacturers - Specialty & Generic -12.15% 84.04% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 21.53% 72.05% Sun Pharma Advanced
SPARC47.41B Healthcare Drug Manufacturers - Specialty & Generic -35.58% -37.00% Aarti Drugs
AARTIDRUGS44.09B Healthcare Drug Manufacturers - Specialty & Generic -19.35% 7.87% Sequent Scientific
SEQUENT43.69B Healthcare Drug Manufacturers - Specialty & Generic 6.29% 51.90% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Parnax Lab Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Parnax Lab's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 13.84%, the Debt to Equity ratio from the most recent quarter is 83.52, and its Gross Profit Margin stands at 43.83%.
- What is the recent revenue and earnings growth for PARNAXLAB?
- Looking at Parnax Lab's growth, its revenue over the trailing twelve months (TTM) was INR2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 6.50%, and quarterly earnings saw a YoY growth of -17.90%.
- How much of PARNAXLAB stock is held by insiders and institutions?
- Wondering who owns Parnax Lab stock? Company insiders (like executives and directors) hold about 73.92% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.